Zenas BioPharma
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1000 Winter St Ste 1200, Waltham, Massac...Phone Number
(857) 271-2954Website
www.zenasbio.comRevenue
-Stock Symbol
ZBIOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Zenas BioPharma
Zenas BioPharma is dedicated to developing therapies for patients with autoimmune diseases, aiming to address significant unmet medical needs and transform their lives. The company is advancing its investigational drug, Obexelimab, which targets B cell activity to help manage various autoimmune conditions. They prioritize understanding the experiences of patients and caregivers to create impactful therapies. Zenas BioPharma is committed to leading in the field of autoimmune disease treatment through its experienced team and innovative approach.Explore more
Zenas BioPharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zenas BioPharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Zenas BioPharma launches new products
Click to see if Zenas BioPharma had a recent Job posting/layoffs
Earning: See what the market has to say on Zenas BioPharma recently announced quarterly report
Funding: Get notified immidiatlly once Zenas BioPharma has new funding data
Website visits: Recent activity has been detected on your website
Check out if Zenas BioPharma is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Zenas BioPharma
Zenas BioPharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Zenas BioPharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Zenas BioPharma
Compare insights from companies similar to Zenas BioPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zenas BioPharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zenas BioPharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zenas BioPharma.
Zenas BioPharma financials insights
Gather financial insights about Zenas BioPharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$118M
2024
Series C
$200M
Zenas BioPharma Tech Stack
A closer look at the technologies used by Zenas BioPharma
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
Zenas BioPharma announced that orelabrutinib is the subject of two Phase III trials one in primary progressive MS with a 12-week composite confirmed disability progression endpoint and one in non-active secondary progressive MS with a 24-week confirmed disability progression endpoint both randomized 2:1 at 80 mg once daily, with data expected in 2030.
Medical Research, Pharmaceuticals
Product Launch
Zenas BioPharma has announced plans to launch obexelimab for IgG4-related disease (IgG4-RD) in H1 of next year, with additional global approvals potentially expected throughout the year.
Product Launch
Project
conducted a survey of 80 physicians two-thirds of whom were rheumatologists evaluating the commercial profile of obexelimab against anti-CD20 and anti-CD19 antibody biologics, with 51% of clinicians agreeing or strongly agreeing on the value of a B-cell inhibitor over a depleter, compared to only 3% who preferred a depleter.
Doctors / Physicians
Project
Medical Research, Pharmaceuticals, Clinical Operations
Zenas BioPharma News & Media
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 -Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 35,750Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
Zenas BioPharma Inc. (NASDAQ:ZBIO) is one of the best IPO stocks with huge upside potential. On June 2, Zenas announced positive results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease. The study met its primary and all key secondary endpoints, demonstrating a 56% reduction in flare risk compared to placebo and […]Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 100,000
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zenas BioPharma
Sign Up For FreeTo access detailed company insights
Zenas BioPharma is dedicated to developing therapies for patients with autoimmune diseases, aiming to address significant unmet medical needs and transform their lives. The company is advancing its investigational drug, Obexelimab, which targets B cell activity to help manage various autoimmune conditions. They prioritize understanding the experien... Read More
